Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14457619 | 0.87 | CNR1 (0.47) | CNR1GPR55ALDH1A1NPSR1SCN9A | |
| SCHEMBL14457581 | 0.87 | SCN9A (0.51) | CNR1GPR55ALDH1A1EDNRBEDNRA | |
| SCHEMBL5659203 | 0.86 | CNR1 (0.52) | CNR1GPR55ALDH1A1NPSR1SCN9A | |
| SCHEMBL5659599 | 0.85 | SCN9A (0.58) | CNR1GPR55EDNRBEDNRASCN9A | |
| SCHEMBL5658420 | 0.84 | MAPT (0.49) | CNR1GPR55ALDH1A1NPSR1SCN9A | |
| SCHEMBL5660616 | 0.83 | CNR1 (0.61) | CNR1GPR55ALDH1A1NPSR1SCN9A | |
| SCHEMBL5659386 | 0.83 | GFER (0.52) | CNR1GPR55ALDH1A1SCN9ASMN1; SMN2 | |
| SCHEMBL5656629 | 0.82 | MAPT (0.47) | CNR1GPR55ALDH1A1EDNRBEDNRA | |
| SCHEMBL5659726 | 0.80 | TP53 (0.52) | CNR1GPR55ALDH1A1EDNRBEDNRA | |
| SCHEMBL5659155 | 0.79 | MAPT (0.50) | CNR1GPR55ALDH1A1NPSR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | CNR1 362/4885GPR55 77/4885ALDH1A1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.